Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease

Current Hepatology Reports

Volumn 15, Issue 2, 2016, Pages 75-85

  VanWagner, Lisa B ^a,b   Rinella, Mary E ^a,b  

^a Sect of Gastroenterol/Nutrition   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bone disease; Cardiovascular disease (CVD); Diabetes; Iron overload; Kidney disease; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Sex hormones; Sleep apnea; Thyroid disease

Indexed keywords

EID: 85019211248     PISSN: None     EISSN: 21959595     Source Type: Journal    
DOI: 10.1007/s11901-016-0295-9     Document Type: Article

References (115)

1. V. Nobili N. Alkhouri A. Alisi C. Della Corte E. Fitzpatrick M. Raponi et al. Nonalcoholic fatty liver disease: a challenge for pediatricians JAMA Pediatr 2015 169 170 6 10.1001/jamapediatrics.2014.2702 25506780
2. C.D. Williams J. Stengel M.I. Asike D.M. Torres J. Shaw M. Contreras et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 2011 140 124 31 10.1053/j.gastro.2010.09.038 20858492
3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–44. Comprehensive review of the evidence that suggests NAFLD is a multisystem disease and the factors that might determine inter-individual variation in the development and progression of its major hepatic and extra-hepatic manifestations (principally type 2 diabetes mellitus and cardiovascular disease). Included are excellent tables summarizing key studies to date assessing associations between NAFLD and T2DM and CVD.
4. G. Vernon A. Baranova Z.M. Younossi Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment Pharmacol Ther 2011 34 274 85 1:STN:280:DC%2BC3MnlsVamsg%3D%3D 10.1111/j.1365-2036.2011.04724.x 21623852
5. M. Machado P. Marques-Vidal H. Cortez-Pinto Hepatic histology in obese patients undergoing bariatric surgery J Hepatol 2006 45 600 6 10.1016/j.jhep.2006.06.013 16899321
6. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60. This review analyzes the mechanisms that relate NAFLD with metabolic syndrome and dyslipidemia and its association with the development and progression of cardiovascular disease.
7. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47–64. Succinctly reviews the factors involved in the progression of liver disease in NAFLD and the factors linking NAFLD with other extra-hepatic chronic diseases, such as T2DM, CVD, and CKD. Includes excellent diagrams and an discussion of pathophysiology linking NAFLD to these conditions.
8. Miele L, Targher G. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. Expert Rev Gastroenterol Hepatol. 2015;9:1243–5. Authors discuss the evidence linking NAFLD with important cardiometabolic complications (mainly Type 2 diabetes and cardiovascular disease) and the putative underlying mechanisms by which NAFLD may contribute to the development of these complications.
9. R.J. Wong M. Aguilar R. Cheung R.B. Perumpail S.A. Harrison Z.M. Younossi et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States Gastroenterology 2015 148 547 55 10.1053/j.gastro.2014.11.039 25461851
10. J.P. Ong A. Pitts Z.M. Younossi Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease J Hepatol 2008 49 608 12 10.1016/j.jhep.2008.06.018 18682312
11. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015.
12. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2014.
13. A. Kotronen J. Westerbacka R. Bergholm K.H. Pietilainen H. Yki-Jarvinen Liver fat in the metabolic syndrome J Clin Endocrinol Metab 2007 92 3490 7 1:CAS:528:DC%2BD2sXhtVGqsrnM 10.1210/jc.2007-0482 17595248
14. Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 201513:1513–1520.e1511.
15. A. Seppala-Lindroos S. Vehkavaara A.M. Hakkinen T. Goto J. Westerbacka A. Sovijarvi et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men J Clin Endocrinol Metab 2002 87 3023 8 1:CAS:528:DC%2BD38XlsVGjsbs%3D 10.1210/jcem.87.7.8638 12107194
16. R.M. Williamson J.F. Price S. Glancy E. Perry L.D. Nee P.C. Hayes et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study Diabetes Care 2011 34 1139 44 10.2337/dc10-2229 21478462 3114489
17. G. Targher L. Bertolini R. Padovani S. Rodella R. Tessari L. Zenari et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients Diabetes Care 2007 30 1212 8 10.2337/dc06-2247 17277038
18. L.A. Adams S. Harmsen J.L. St Sauver P. Charatcharoenwitthaya F.B. Enders T. Therneau et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study Am J Gastroenterol 2010 105 1567 73 10.1038/ajg.2010.18 20145609 2898908
19. G. Targher L. Bertolini S. Rodella G. Zoppini G. Lippi C. Day et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients Diabetologia 2008 51 444 50 1:CAS:528:DC%2BD1cXhtlylsL0%3D 10.1007/s00125-007-0897-4 18058083
20. G. Targher L. Bertolini S. Rodella G. Lippi G. Zoppini M. Chonchol Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis Clin J Am Soc Nephrol 2010 5 2166 71 1:CAS:528:DC%2BC3MXpsVKmsw%3D%3D 10.2215/CJN.05050610 20724519 2994076
21. G. Targher L. Bertolini M. Chonchol S. Rodella G. Zoppini G. Lippi et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients Diabetologia 2010 53 1341 8 1:CAS:528:DC%2BC3cXmsFyrtLw%3D 10.1007/s00125-010-1720-1 20369224
22. V. Ratziu S. Bellentani H. Cortez-Pinto C. Day G. Marchesini A position statement on NAFLD/NASH based on the EASL 2009 special conference J Hepatol 2010 53 372 84 10.1016/j.jhep.2010.04.008 20494470
23. N. Chalasani Z. Younossi J.E. Lavine A.M. Diehl E.M. Brunt K. Cusi et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association Hepatology 2012 55 2005 23 10.1002/hep.25762 22488764
24. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. Jama. 2015;313:2263–73. Recently published review on the epidemiology and determinants of NAFLD including an evidence-based diagnostic algorithm for clinicians.
25. Goessling W, Massaro JM, Vasan RS, D’Agostino RB, Sr., Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008;135:1935–1944, 1944.e1931.
26. E.S. Ford M.B. Schulze M.M. Bergmann C. Thamer H.G. Joost H. Boeing Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study Diabetes Care 2008 31 1138 43 10.2337/dc07-2159 18346992
27. L.A. Adams O.R. Waters M.W. Knuiman R.R. Elliott J.K. Olynyk NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study Am J Gastroenterol 2009 104 861 7 10.1038/ajg.2009.67 19293782
28. A. Fraser R. Harris N. Sattar S. Ebrahim G. Davey Smith D.A. Lawlor Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis Diabetes Care 2009 32 741 50 1:CAS:528:DC%2BD1MXltFSksL8%3D 10.2337/dc08-1870 19131466 2660465
29. G. Musso R. Gambino M. Cassader G. Pagano Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 2011 43 617 49 10.3109/07853890.2010.518623 21039302
30. M. Shibata Y. Kihara M. Taguchi M. Tashiro M. Otsuki Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men Diabetes Care 2007 30 2940 4 1:CAS:528:DC%2BD2sXhtlKhs7vF 10.2337/dc07-0792 17666460
31. J.G. Fan F. Li X.B. Cai Y.D. Peng Q.H. Ao Y. Gao Effects of nonalcoholic fatty liver disease on the development of metabolic disorders J Gastroenterol Hepatol 2007 22 1086 91 1:CAS:528:DC%2BD2sXpsFarsbw%3D 10.1111/j.1440-1746.2006.04781.x 17608855
32. C.H. Kim J.Y. Park K.U. Lee J.H. Kim H.K. Kim Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults Diabet Med 2008 25 476 81 1:CAS:528:DC%2BD1cXmsFKgtrk%3D 10.1111/j.1464-5491.2008.02410.x 18346164
33. T. Yamada M. Fukatsu S. Suzuki T. Wada T. Yoshida T. Joh Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup J Gastroenterol Hepatol 2010 25 352 6 1:CAS:528:DC%2BC3cXjtlGmsLg%3D 10.1111/j.1440-1746.2009.05998.x 19817963
34. K.C. Sung W.S. Jeong S.H. Wild C.D. Byrne Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes Diabetes Care 2012 35 717 22 1:CAS:528:DC%2BC38Xmt1ChsrY%3D 10.2337/dc11-1853 22338098 3308286
35. M. Ekstedt L.E. Franzen U.L. Mathiesen L. Thorelius M. Holmqvist G. Bodemar et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 2006 44 865 73 1:CAS:528:DC%2BD28XhtFyqsrzN 10.1002/hep.21327 17006923
36. E. Bonora G. Targher Increased risk of cardiovascular disease and chronic kidney disease in NAFLD Nat Rev Gastroenterol Hepatol 2012 9 372 81 1:CAS:528:DC%2BC38Xpsl2murY%3D 10.1038/nrgastro.2012.79 22565095
37. J.C. Sirota K. McFann G. Targher R.J. Johnson M. Chonchol D.I. Jalal Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey Metabolism 2013 62 392 9 1:CAS:528:DC%2BC38XhsVCns7jP 10.1016/j.metabol.2012.08.013 23036645 3565047
38. G. Targher Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease J Hepatol 2006 45 879 81 1:CAS:528:DC%2BD28XhtFeqtLvO 10.1016/j.jhep.2006.09.005 17049665 author reply 881–872
39. P.G. Northup C.K. Argo N. Shah S.H. Caldwell Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications Semin Liver Dis 2012 32 39 48 1:CAS:528:DC%2BC38XmsFemtL4%3D 10.1055/s-0032-1306425 22418887
40. E. Bugianesi U. Pagotto R. Manini E. Vanni A. Gastaldelli R. de Iasio et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity J Clin Endocrinol Metab 2005 90 3498 504 1:CAS:528:DC%2BD2MXkvFCltLs%3D 10.1210/jc.2004-2240 15797948
41. S. Akabame M. Hamaguchi K. Tomiyasu M. Tanaka Y. Kobayashi-Takenaka K. Nakano et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT) Circ J 2008 72 618 25 10.1253/circj.72.618 18362435
42. N. Villanova S. Moscatiello S. Ramilli E. Bugianesi D. Magalotti E. Vanni et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease Hepatology 2005 42 473 80 10.1002/hep.20781 15981216
43. H. Volzke D.M. Robinson V. Kleine R. Deutscher W. Hoffmann J. Ludemann et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis World J Gastroenterol 2005 11 1848 53 10.3748/wjg.v11.i12.1848 15793879 4305889
44. D. Kim S.Y. Choi E.H. Park W. Lee J.H. Kang W. Kim et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification Hepatology 2012 56 605 13 1:CAS:528:DC%2BC38XhtVylu77L 10.1002/hep.25593 22271511
45. L.B. VanWagner H. Ning C.E. Lewis C.M. Shay J. Wilkins J.J. Carr et al. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the coronary artery risk development in young adults study Atherosclerosis 2014 235 599 605 1:CAS:528:DC%2BC2cXhtFCiurnF 10.1016/j.atherosclerosis.2014.05.962 24956534 4124046
46. M. Stepanova Z.M. Younossi Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population Clin Gastroenterol Hepatol 2012 10 646 50 10.1016/j.cgh.2011.12.039 22245962
47. M. Lazo R. Hernaez S. Bonekamp I.R. Kamel F.L. Brancati E. Guallar et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study BMJ 2011 343 d6891 10.1136/bmj.d6891 22102439 3220620
48. Y.C. Lin H.M. Lo J.D. Chen Sonographic fatty liver, overweight and ischemic heart disease World J Gastroenterol 2005 11 4838 42 10.3748/wjg.v11.i31.4838 16097054 4398732
49. A. Fraser R. Harris N. Sattar S. Ebrahim G.D. Smith D.A. Lawlor Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women’s Heart and Health Study and Meta-Analysis Arterioscler Thromb Vasc Biol 2007 27 2729 35 1:CAS:528:DC%2BD2sXhtlahtLvP 10.1161/ATVBAHA.107.152298 17932318
50. G. Perseghin G. Lattuada F. De Cobelli A. Esposito E. Belloni G. Ntali et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver Hepatology 2008 47 51 8 1:CAS:528:DC%2BD1cXhtlCiu7s%3D 10.1002/hep.21983 17955548
51. R. Lautamaki R. Borra P. Iozzo M. Komu T. Lehtimaki M. Salmi et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes Am J Physiol Endocrinol Metab 2006 291 E282 90 1:CAS:528:DC%2BD28XovVWgt74%3D 10.1152/ajpendo.00604.2005 16478772
52. L. Pacifico M. Di Martino A. De Merulis M. Bezzi J.F. Osborn C. Catalano et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease Hepatology 2014 59 461 70 1:CAS:528:DC%2BC2cXhslygtLw%3D 10.1002/hep.26610 23843206
53. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 2015.
54. R. Dhingra P. Gona T.J. Wang C.S. Fox R.B. D’Agostino Sr R.S. Vasan Serum gamma-glutamyl transferase and risk of heart failure in the community Arterioscler Thromb Vasc Biol 2010 30 1855 60 1:CAS:528:DC%2BC3cXhtVCnsbjM 10.1161/ATVBAHA.110.207340 20539015 2924453
55. Y. Wang J. Tuomilehto P. Jousilahti V. Salomaa B. Li R. Antikainen et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland Heart 2013 99 163 7 1:CAS:528:DC%2BC3sXislyhsro%3D 10.1136/heartjnl-2012-302972 23144292
56. S.G. Wannamethee P.H. Whincup A.G. Shaper L. Lennon N. Sattar Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men Arterioscler Thromb Vasc Biol 2012 32 830 5 1:CAS:528:DC%2BC38XisVynu74%3D 10.1161/ATVBAHA.111.240457 22223732
57. S. Ballestri A. Lonardo S. Bonapace C.D. Byrne P. Loria G. Targher Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease World J Gastroenterol 2014 20 1724 45 1:CAS:528:DC%2BC2cXhtlOgt77E 10.3748/wjg.v20.i7.1724 24587651 3930972
58. G. Targher F. Valbusa S. Bonapace L. Bertolini L. Zenari S. Rodella et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes PLoS One 2013 8 e57183 1:CAS:528:DC%2BC3sXjslChtLc%3D 10.1371/journal.pone.0057183 23451184 3579814
59. G. Targher F. Valbusa S. Bonapace L. Bertolini L. Zenari I. Pichiri et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes Nutr Metab Cardiovasc Dis 2014 24 663 9 10.1016/j.numecd.2014.01.005 24594085
60. J.L. Newton J. Pairman K. Wilton D.E.J. Jones C. Day Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease Clin Auton Res 2009 19 319 26 10.1007/s10286-009-0031-4 19768633
61. D. Kim W.R. Kim H.J. Kim T.M. Therneau Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States Hepatology 2013 57 1357 65 1:CAS:528:DC%2BC3sXlslygu7o%3D 10.1002/hep.26156 23175136 3622816
62. L.B. Vanwagner M. Bhave H.S. Te J. Feinglass L. Alvarez M.E. Rinella Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events Hepatology 2012 56 1741 50 10.1002/hep.25855 22611040
63. VanWagner LB, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int 2015.
64. M. Albeldawi A. Ashish S. Madhwal J. Cywinski R. Lopez B. Eghtesad Zein NN 2011 Liver Transpl Cumulative risk of cardiovascular events following orthotopic liver transplantation
65. G. Targher M. Chonchol G. Zoppini C. Abaterusso E. Bonora Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 2011 54 1020 9 1:CAS:528:DC%2BC3MXkvFGhur0%3D 10.1016/j.jhep.2010.11.007 21145850
66. G. Musso M. Cassader S. Cohney S. Pinach F. Saba R. Gambino Emerging liver-kidney interactions in nonalcoholic fatty liver disease Trends Mol Med 2015 21 645 62 1:CAS:528:DC%2BC2MXhsF2kurjI 10.1016/j.molmed.2015.08.005 26432021
67. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680. High-quality systematic review evaluating the current literature on the association between NAFLD and CKD.
68. Musso G, Gambino R, Cassader M. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. In: Annual Review of Medicine; 2010. p. 375–392.
69. M.F. Abdelmalek A. Suzuki C. Guy A. Unalp-Arida R. Colvin R.J. Johnson et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease Hepatology 2010 51 1961 71 1:CAS:528:DC%2BC3cXnslyqsbg%3D 10.1002/hep.23535 20301112 2922495
70. W. Cheungpasitporn C. Thongprayoon O.A. O’Corragain P.J. Edmonds W. Kittanamongkolchai S.B. Erickson Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis Nephrology (Carlton) 2014 19 791 7 1:CAS:528:DC%2BC2cXhvFGmsb7E 10.1111/nep.12343
71. R. Heinzer S. Vat P. Marques-Vidal H. Marti-Soler D. Andries N. Tobback et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study Lancet Respir Med 2015 3 310 8 1:STN:280:DC%2BC2MrlsVGisg%3D%3D 10.1016/S2213-2600(15)00043-0 25682233 4404207
72. J.P. Baguet G. Barone-Rochette R. Tamisier P. Levy J.L. Pepin Mechanisms of cardiac dysfunction in obstructive sleep apnea Nat Rev Cardiol 2012 9 679 88 1:CAS:528:DC%2BC38Xhslalu7zF 10.1038/nrcardio.2012.141 23007221
73. F. Tanne F. Gagnadoux O. Chazouilleres B. Fleury D. Wendum E. Lasnier et al. Chronic liver injury during obstructive sleep apnea Hepatology 2005 41 1290 6 10.1002/hep.20725 15915459
74. P. Jouet J.M. Sabate D. Maillard S. Msika C. Mechler S. Ledoux et al. Relationship between obstructive sleep apnea and liver abnormalities in morbidly obese patients: a prospective study Obes Surg 2007 17 478 85 10.1007/s11695-007-9085-3 17608260
75. V. Savransky A. Nanayakkara A. Vivero J. Li S. Bevans P.L. Smith et al. Chronic intermittent hypoxia predisposes to liver injury Hepatology 2007 45 1007 13 1:CAS:528:DC%2BD2sXltlWitL8%3D 10.1002/hep.21593 17393512
76. J. Aron-Wisnewsky C. Minville J. Tordjman P. Levy J.L. Bouillot A. Basdevant et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese J Hepatol 2012 56 225 33 1:CAS:528:DC%2BC3MXhs1GhsbjE 10.1016/j.jhep.2011.04.022 21703181
77. P. Mishra C. Nugent A. Afendy C. Bai P. Bhatia M. Afendy et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis Liver Int 2008 28 1080 6 1:CAS:528:DC%2BD1cXhtFWmsL%2FP 10.1111/j.1478-3231.2008.01822.x 18647236
78. V.Y. Polotsky S.P. Patil V. Savransky A. Laffan S. Fonti L.A. Frame et al. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity Am J Respir Crit Care Med 2009 179 228 34 10.1164/rccm.200804-608OC 18990675 2633055
79. K.E. Corey J. Misdraji L. Gelrud L.Y. King H. Zheng A. Malhotra et al. Obstructive sleep apnea is associated with nonalcoholic steatohepatitis and advanced liver histology Dig Dis Sci 2015 60 2523 8 10.1007/s10620-015-3650-8 25840922
80. Sundaram SS, Sokol RJ, Capocelli KE, Pan Z, Sullivan JS, Robbins K, Halbower AC. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J Pediatr 2014;164:699–706.e691.
81. C. Minville M.N. Hilleret R. Tamisier J. Aron-Wisnewsky K. Clement C. Trocme et al. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea Chest 2014 145 525 33 10.1378/chest.13-0938 24264333
82. G. Musso M. Cassader C. Olivetti F. Rosina G. Carbone R. Gambino Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis Obes Rev 2013 14 417 31 1:CAS:528:DC%2BC3sXmt1Ohu7Y%3D 10.1111/obr.12020 23387384
83. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174–97. Excellent comprehensive review on the extrahepatic complicaions of NAFLD focusing primarily on T2DM, CVD, CKD and colorectal cancer.
84. I.A. Nakchbandi S.W. van der Merwe Current understanding of osteoporosis associated with liver disease Nat Rev Gastroenterol Hepatol 2009 6 660 70 10.1038/nrgastro.2009.166 19881518
85. G. Targher A. Lonardo M. Rossini Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest 2015 38 817 25 1:CAS:528:DC%2BC28XhvFSjtbk%3D 10.1007/s40618-015-0315-6 26003827
86. M. Li Y. Xu M. Xu L. Ma T. Wang Y. Liu et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese J Clin Endocrinol Metab 2012 97 2033 8 1:CAS:528:DC%2BC38Xos1eisrw%3D 10.1210/jc.2011-3010 22466338
87. G.E. Chung D. Kim W. Kim J.Y. Yim M.J. Park Y.J. Kim et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism J Hepatol 2012 57 150 6 1:CAS:528:DC%2BC38XovV2nsr4%3D 10.1016/j.jhep.2012.02.027 22425701
88. A. Eshraghian J.A. Hamidian Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review World J Gastroenterol 2014 20 8102 9 10.3748/wjg.v20.i25.8102 25009382 4081681
89. M.R. Pagadala C.O. Zein S. Dasarathy L.M. Yerian R. Lopez A.J. McCullough Prevalence of hypothyroidism in nonalcoholic fatty liver disease Dig Dis Sci 2012 57 528 34 10.1007/s10620-011-2006-2 22183820 3922233
90. C.E. Kelley A.J. Brown A.M. Diehl T.L. Setji Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome World J Gastroenterol 2014 20 14172 84 10.3748/wjg.v20.i39.14172 25339805 4202347
91. M. Ramezani-Binabaj M. Motalebi H. Karimi-Sari M.S. Rezaee-Zavareh S.M. Alavian Are women with polycystic ovarian syndrome at a high risk of non-alcoholic fatty liver disease; a meta-analysis Hepat Mon 2014 14 e23235 10.5812/hepatmon.23235 25598791 4286712
92. Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine 2015.
93. J. Ferlay H.R. Shin F. Bray D. Forman C. Mathers D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 2010 127 2893 917 1:CAS:528:DC%2BC3cXhtlWhs7fO 10.1002/ijc.25516 21351269
94. R. Jinjuvadia P. Lohia C. Jinjuvadia S. Montoya S. Liangpunsakul The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis J Clin Gastroenterol 2013 47 33 44 10.1097/MCG.0b013e3182688c15 23090040 3518571
95. H. Shen S. Lipka A. Kumar P. Mustacchia Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis J Gastrointest Oncol 2014 5 440 6 25436123 4226833
96. G. Ganzetti A. Campanati A. Offidani Non-alcoholic fatty liver disease and psoriasis: so far, so near World J Hepatol 2015 7 315 26 10.4254/wjh.v7.i3.315 25848461 4381160
97. L. Mallbris C.T. Ritchlin M. Stahle Metabolic disorders in patients with psoriasis and psoriatic arthritis Curr Rheumatol Rep 2006 8 355 63 1:CAS:528:DC%2BD28XhtFGrt7fN 10.1007/s11926-006-0065-8 16973109
98. E.A. van der Voort E.M. Koehler E.A. Dowlatshahi A. Hofman B.H. Stricker H.L. Janssen et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study J Am Acad Dermatol 2014 70 517 24 10.1016/j.jaad.2013.10.044 24373781
99. L. Miele S. Vallone C. Cefalo G. La Torre C. Di Stasi F.M. Vecchio et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis J Hepatol 2009 51 778 86 1:CAS:528:DC%2BD1MXhtFagt7%2FP 10.1016/j.jhep.2009.06.008 19664838
100. K.K. Roberts A.E. Cochet P.B. Lamb P.J. Brown D.F. Battafarano E.M. Brunt et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic Aliment Pharmacol Ther 2015 41 293 300 1:STN:280:DC%2BC2Mzot1yhtw%3D%3D 10.1111/apt.13042 25521607
101. P. Gisondi G. Targher G. Zoppini G. Girolomoni Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis J Hepatol 2009 51 758 64 1:CAS:528:DC%2BD1MXhtFagt77E 10.1016/j.jhep.2009.04.020 19560226
102. M.H. Mendler B. Turlin R. Moirand A.M. Jouanolle T. Sapey D. Guyader et al. Insulin resistance-associated hepatic iron overload Gastroenterology 1999 117 1155 63 1:STN:280:DC%2BD3c%2FgsF2itQ%3D%3D 10.1016/S0016-5085(99)70401-4 10535879
103. R. Moirand A.M. Mortaji O. Loreal F. Paillard P. Brissot Y. Deugnier A new syndrome of liver iron overload with normal transferrin saturation Lancet 1997 349 95 7 1:STN:280:DyaK2s7kvFKitg%3D%3D 10.1016/S0140-6736(96)06034-5 8996422
104. K.V. Kowdley P. Belt L.A. Wilson M.M. Yeh B.A. Neuschwander-Tetri N. Chalasani et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease Hepatology 2012 55 77 85 1:CAS:528:DC%2BC3MXhs1Ght77J 10.1002/hep.24706 21953442 3245347
105. Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, Liaquat H, et al. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:1163–1169.e1161.
106. J.E. Nelson L. Wilson E.M. Brunt M.M. Yeh D.E. Kleiner A. Unalp-Arida et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease Hepatology 2011 53 448 57 1:CAS:528:DC%2BC3MXisVGis7g%3D 10.1002/hep.24038 21274866 3058264
107. P. Sorrentino S. D’Angelo U. Ferbo P. Micheli A. Bracigliano R. Vecchione Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis J Hepatol 2009 50 351 7 1:CAS:528:DC%2BD1MXntVGhuw%3D%3D 10.1016/j.jhep.2008.09.011 19070395
108. L. Valenti A.L. Fracanzani P. Dongiovanni E. Bugianesi G. Marchesini P. Manzini et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case–control study Am J Gastroenterol 2007 102 1251 8 1:CAS:528:DC%2BD2sXotFaitr8%3D 10.1111/j.1572-0241.2007.01192.x 17391316
109. A. Guillygomarc’h M.H. Mendler R. Moirand F. Laine V. Quentin V. David et al. Venesection therapy of insulin resistance-associated hepatic iron overload J Hepatol 2001 35 344 9 10.1016/S0168-8278(01)00147-7 11592595
110. L.A. Adams D.H. Crawford K. Stuart House MJ T.G. St Pierre M. Webb et al. The impact of phlebotomy in nonalcoholic fatty liver disease: a prospective, randomized, controlled trial Hepatology 2015 61 1555 64 1:CAS:528:DC%2BC2MXmslWlsbo%3D 10.1002/hep.27662 25524401
111. V.H. Ajmera L.B. VanWagner E.P. Gunderson C.E. Lewis J.J. Carr T. NA T Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease 2015 Washington, DC In Digestive Diseases Week
112. D.C. Goff Jr D.M. Lloyd-Jones G. Bennett S. Coady R.B. D’Agostino Sr R. Gibbons et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2014 63 2935 59 10.1016/j.jacc.2013.11.005 24239921
113. N.J. Stone J.G. Robinson A.H. Lichtenstein C.N. Bairey Merz C.B. Blum R.H. Eckel et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2014 63 2889 934 10.1016/j.jacc.2013.11.002 24239923
114. K.F. Murray R.L. Carithers Jr AASLD practice guidelines: evaluation of the patient for liver transplantation Hepatology 2005 41 1407 32 10.1002/hep.20704 15880505
115. D.K. Rex D.A. Johnson J.C. Anderson P.S. Schoenfeld C.A. Burke J.M. Inadomi American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected] Am J Gastroenterol 2009 104 739 50 10.1038/ajg.2009.104 19240699